Table 1.
Demographic and general characteristics of patients with psoriasis by treatment group prior to FAE therapy initiation; total number of patients = 859
| FAE monotherapy | FAEs + phototherapy | FAEs + MTX | All | P‐value | |
|---|---|---|---|---|---|
| Patients initiating FAE therapy, N (%) | 626 (72.9) | 123 (14.3) | 110 (12.8) | 859 (100.0) | |
| Sex | |||||
| Male, n (%) | 388 (62.0) | 77 (62.6) | 63 (57.3) | 528 (61.5) | 0.62* |
| Female, n (%) | 238 (38.0) | 46 (37.4) | 47 (42.7) | 331 (38.5) | |
| Age (years) | |||||
| Mean ± SD | 45.9 ± 14.6 | 48.3 ± 15.5 | 46.7 ± 14.2 | 46.3 ± 14.7 | 0.22** |
| Median (range) | 46.0 (9.0−89.0) | 47.0 (11.0−90.0) | 47.5 (18.0−89.0) | 46.0 (9.0−90.0) | |
| BMI (kg/m 2 ), n (% of N ) | 111 (17.7) | 55 (44.7) | 56 (50.9) | 222 (25.8) | |
| Mean ± SD | 28.6 ± 6.6 | 29.1 ± 6.2 | 29.4 ± 7.8 | 28.9 ± 6.8 | 0.75** |
| Median (range) | 27.3 (18.0−51.0) | 28.0 (19.7−52.0) | 27.5 (19.0−60.0) | 27.8 (18.0−60.0) | |
| Family history of psoriasis, n (% of N ) | 421 (67.3) | 85 (69.1) | 88 (80.0) | 594 (69.2) | |
| Positive, n (%) | 137 (32.5) | 26 (30.6) | 31 (35.2) | 194 (32.7) | 0.81* |
| Negative, n (%) | 284 (67.5) | 59 (69.4) | 57 (64.8) | 400 (67.3) | |
| Smoking status, n (% of N ) | 150 (24.0) | 58 (47.2) | 62 (56.4) | 270 (31.4) | |
| Positive/current, n (%) | 93 (62.0) | 33 (56.9) | 35 (56.5) | 161 (59.6) | 0.67* |
| Negative, n (%) | 57 (38.0) | 25 (43.1) | 27 (43.5) | 109 (40.4) | |
| Employment status, n (% of N ) | 203 (32.4) | 55 (44.7) | 56 (50.9) | 314 (36.6) | |
| Employed, n (%) | 149 (73.4) | 36 (65.5) | 38 (67.9) | 223 (71.0) | 0.44* |
| Unemployed/retired, n (%) | 54 (26.6) | 19 (34.5) | 18 (32.1) | 91 (29.0) | |
*P‐value derived from chi‐square test; **P‐value derived from one‐way analysis of variance (ANOVA).
FAEs, fumaric acid esters; phototherapy, ultraviolet A, ultraviolet B or psoralen + ultraviolet A; MTX, methotrexate; n, number of patients with available data; SD, standard deviation; BMI, body mass index.